FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in patients with metastatic (Stage IV) disease * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Measurable disease by RECIST criteria * Adequate organ system function, as defined by protocol Exclusion Criteria: * Prior systemic or radiation therapy for metastatic colorectal cancer * Adjuvant chemotherapy (and/or chemoradiation) for colorectal cancer within 12 months prior to date of diagnosis of metastatic disease * Previously untreated brain metastases * History of hypersensitivity to active or inactive excipients of any component of treatment, or known dipyrimidine dehydrogenase deficiency * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * History of hematemesis or hemoptysis \</= 1 months prior to study enrollment * Significant cardiovascular disease or disorder * History of abdominal fistula or gastrointestinal perforation \</= 6 months prior to Day 1 * Positive for hepatitis B, hepatitis C or HIV infection * Other active cancers or history of treatment for invasive cancer within the last 5 years, except for non-melanoma skin cancer